Key result
Transapical TAVR resulted in a periprocedural mortality of 1.9% and freedom from cardiovascular mortality of 75.7% at 3 years and 60.2% at 5 years.
Why the study?
TA-TAVR is linked to higher morbidity than TF-TAVR but remains an alternative for unsuitable patients, and outcomes depend on operator expertise.
Does transapical transcatheter aortic valve replacement (TA-TAVR) provide safe and effective outcomes in patients unsuitable for transfemoral TAVR?
Population
154 consecutive patients undergoing TA-TAVR
Design
Single-centre observational cohort study
Follow-up
Up to 5 years
Authors
Loading...
TA-TAVR by expert teams yielded acceptable short- and mid-term outcomes; leaves open generalizability beyond high-volume centres.
Cohort (n=154)
No
Does transapical transcatheter aortic valve replacement (TA-TAVR) provide safe and effective outcomes in patients unsuitable for transfemoral TAVR?
TA-TAVR is a safe and effective alternative for patients unsuitable for transfemoral access, with low periprocedural mortality (1.9%) when performed by an expert Heart-Team.
Francica et al. (2022) conducted a cohort in Aortic valve disease unsuitable for transfemoral TAVR (n=154). Transapical Transcatheter Aortic Valve Replacement (TA-TAVR) was evaluated on Short- and mid-term major clinical events according to VARC-3 criteria. Transapical TAVR resulted in a periprocedural mortality of 1.9% and freedom from cardiovascular mortality of 75.7% at 3 years and 60.2% at 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: